Drugs / KL-A167
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT07371208 | Dec 2025 → Aug 2028 expected | breast cancer | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT05445908 | Aug 2022 → Sep 2027 expected | breast carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05351788 | May 2022 → Aug 2026 overdue | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT03848286 | Mar 2019 → Jul 2021 | metastatic malignant neoplasm, nasopharyngeal carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03580564 | Aug 2018 → Aug 2020 | classic Hodgkin lymphoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05294172 | Jun 2022 → Dec 2027 expected | metastatic carcinoma, nasopharyngeal carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07296809 Background | Jan 2026 → Dec 2028 expected | small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-08-19 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Results Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC kelun-biotech.com ↗ |
| 2025-01-21 | Klus Pharma Inc. | Regulatory Kelun-Biotech’s Product Tagitanlimab Approved for Marketing for Second Indication in China kluspharma.com ↗ |
| 2025-01-21 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech’s Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC kelun-biotech.com ↗ |
| 2025-01-03 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech's Anti-PD-L1 (Tagitanlima）Receives NMPA Approval for Marketing kelun-biotech.com ↗
This is the world's first PD-L1 monoclonal antibody approved for the treatment of NPC. |
| 2024-12-31 | Klus Pharma Inc. | Regulatory Kelun-Biotech's Anti-PD-L1 (Tagitanlimab) Receives NMPA Approval for Marketing kluspharma.com ↗
This marks the world's first PD-L1 monoclonal antibody approved for the treatment of NPC. |
| 2024-09-29 | Klus Pharma Inc. | Results Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Presented at 2024 CSCO Congress kluspharma.com ↗
After median follow up of 14.0 mo and 6.9 mo for cohort 1A and 1B, the ORR was 48.6% (18/37, 2 pending confirmation), DCR was 94.6% and median PFS was 15.4 mo (95% CI: 6.7, NE) |
| 2024-09-29 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Results Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) At 2024 CSCO Congress kelun-biotech.com ↗
After median follow up of 14.0 mo and 6.9 mo for cohort 1A and 1B, the ORR was 48.6% (18/37, 2 pending confirmation), DCR was 94.6% and median PFS was 15.4 mo |
| 2024-05-24 | Klus Pharma Inc. | Results Two Abstracts of SKB264/sac-TMT (TROP2 ADC) published at 2024 ASCO Annual Meeting kluspharma.com ↗
At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Illinois from May 31 to June 4, 2024, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) will present the latest results from two clinical studies. |
| 2024-05-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Results ASCO 2024| Two Abstracts of the Study Results of Kelun-Biotech’s TROP2-ADC SKB264/sac-TMT Published Today–OptiTROP-Breast01 study AND the OptiTROP-Lung01 study kelun-biotech.com ↗
The abstracts for the above studies were published on ASCO’s official website on [May 23, 2024], local time. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KL-A167 | “combined with KL-A167 (900 mg, Day 1, every 2 weeks)” NCT07371208 ↗ |
| Route | Intravenous | “900 mg intravenously (IV)” NCT03580564 ↗ |